# CHRM1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The CHRM1 gene encodes the M1 muscarinic acetylcholine receptor, a Gq/11-coupled G protein-coupled receptor predominantly found in the cerebral cortex and hippocampus, crucial for slow excitatory neurotransmission and cognitive processes. - CHRM1 signaling canonically activates phospholipase C (PLC), leading to intracellular calcium mobilization and diacylglycerol production, but also engages non-canonical pathways like MAPK/ERK and PI3K/Akt. - Dysregulation of CHRM1 is implicated in neurodegenerative diseases such as Alzheimer's disease and schizophrenia, as well as various cancers, making it a significant therapeutic target. - The CHRM1 gene's structure includes a single coding exon and regulatory elements in its 5' and 3' untranslated regions, allowing for transcriptional and post-transcriptional modulation, including alternative polyadenylation affecting miRNA binding. - High-resolution structural data, including PDB: 6OIJ, reveals CHRM1's seven-transmembrane architecture, the orthosteric binding pocket for acetylcholine, and an allosteric site amenable to subtype-selective modulators. - Pathogenic germline variants in CHRM1 are rare but have been associated with autonomic dysfunction, while somatic mutations, particularly gain-of-function variants in gastric cancer, contribute to tumorigenesis. --- ## Executive Summary & Key Metadata The cholinergic receptor muscarinic 1 (CHRM1) gene encodes the M1 muscarinic acetylcholine receptor, a prototypical class A G protein-coupled receptor (GPCR) that mediates the metabotropic actions of the neurotransmitter acetylcholine (ACh). CHRM1 is the predominant muscarinic receptor subtype in the cerebral cortex and hippocampus, where it orchestrates slow excitatory neurotransmission, synaptic plasticity, and cognitive processes. Beyond the central nervous system (CNS), CHRM1 is expressed in autonomic ganglia, salivary glands, and various peripheral tissues, where it modulates secretion, smooth muscle contraction, and cardiac chronotropy. The receptor's signaling is canonically coupled to the Gq/11 family of heterotrimeric G proteins, activating phospholipase C (PLC) and mobilizing intracellular calcium. However, CHRM1 also engages multiple non-canonical pathways, including mitogen-activated protein kinase (MAPK) cascades, phosphoinositide 3-kinase (PI3K)/Akt signaling, and direct modulation of ion channels. Given its central role in cognition and its dysregulation in Alzheimer's disease (AD), schizophrenia, and multiple malignancies, CHRM1 represents a high-value therapeutic target. This reference manual provides an exhaustive analysis of the CHRM1 gene, from its genomic architecture and protein structure to its signaling networks, pathogenic mutations, and pharmacogenomic landscape. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | CHRM1 | | **UniProt Accession** | P11229 | | **Representative PDB ID** | 6OIJ (active-state M1 receptor bound to iperoxo) | | **Chromosomal Locus** | 11q13.2 (GRCh38: chr11:62,908,679–62,921,878, minus strand) | | **Primary Molecular Function** | Gq/11-coupled muscarinic acetylcholine receptor; mediates slow excitatory neurotransmission, PLC activation, and calcium mobilization | | **Disease & Pathology Associations** | Alzheimer's disease (cognitive decline), schizophrenia (negative/cognitive symptoms), multiple cancers (gastric, lung, breast, glioblastoma), autonomic neuropathies, and congenital disorders of glycosylation (secondary) | | **Expression Pattern** | High in CNS (cortex, hippocampus, striatum); peripheral: salivary glands, gastric parietal cells, sympathetic ganglia, smooth muscle | | **Pharmacological Class** | Class A (Rhodopsin-like) GPCR; target of orthosteric and allosteric modulators | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The CHRM1 gene is located on the long arm of chromosome 11 at cytogenetic band 11q13.2. In the GRCh38 assembly, CHRM1 spans approximately 13.2 kilobases (kb) of genomic DNA, from position 62,908,679 to 62,921,878 on the minus (reverse) strand. The gene is composed of a single coding exon, a feature shared by most GPCR genes, which lack introns in their open reading frames (ORFs). The absence of introns within the coding sequence has significant evolutionary and regulatory implications: it permits rapid translation of the receptor protein but eliminates the possibility of alternative splicing within the ORF. However, the 5' untranslated region (UTR) and 3' UTR are interrupted by introns, allowing for regulatory complexity at the transcriptional and post-transcriptional levels. The CHRM1 locus resides within a gene-dense region of chromosome 11 that contains several other clinically relevant genes, including *CCND1* (cyclin D1), *FGF19*, *FGF4*, *FGF3*, and *ORAOV1*. This genomic neighborhood is frequently amplified in human cancers, particularly in head and neck squamous cell carcinoma and breast cancer, where the 11q13 amplicon is a well-characterized driver of tumorigenesis. The proximity of CHRM1 to these oncogenes raises the possibility of co-amplification events, although the functional contribution of CHRM1 overexpression in these amplicons remains an area of active investigation. ### 1.2 Promoter Architecture and Transcriptional Regulation The CHRM1 promoter lacks a canonical TATA box, a characteristic shared with many GPCR genes. Instead, transcription initiation is governed by a GC-rich region containing multiple Sp1 (specificity protein 1) binding sites. Functional promoter analysis has identified a minimal promoter region spanning approximately 200 base pairs upstream of the transcription start site (TSS) that is sufficient to drive basal expression. Within this region, several cis-regulatory elements have been characterized: - **Sp1/Sp3 binding sites**: These ubiquitous transcription factors are essential for basal CHRM1 transcription. Sp1 binding at positions −60 to −50 and −120 to −110 relative to the TSS has been confirmed by electrophoretic mobility shift assays (EMSAs) and chromatin immunoprecipitation (ChIP). Sp3, which shares DNA-binding specificity with Sp1, can act as either an activator or repressor depending on the cellular context. - **E-box elements**: Two E-box motifs (CANNTG) are present in the proximal promoter, which serve as binding sites for basic helix-loop-helix (bHLH) transcription factors. The neuronal bHLH factor NeuroD1 has been shown to bind one of these E-boxes and activate CHRM1 transcription in neuronal cells. This regulatory mechanism likely contributes to the neuron-specific expression pattern of CHRM1. - **cAMP response element (CRE)**: A CRE-like sequence at position −180 to −173 mediates transcriptional activation in response to elevated intracellular cAMP. This element binds CREB (cAMP response element-binding protein) and provides a mechanism for activity-dependent regulation of CHRM1 expression. Given that CHRM1 activation can itself modulate cAMP levels through Gs coupling under certain conditions, this CRE may participate in a positive feedback loop. - **Repressor elements**: A silencer region has been mapped to the distal promoter (positions −500 to −300) that binds the transcriptional repressor REST (RE1-silencing transcription factor, also known as NRSF). REST binding at this site maintains low CHRM1 expression in non-neuronal tissues, and its release during neuronal differentiation permits robust CHRM1 upregulation. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin conformation capture studies (Hi-C and 3C) have identified several putative enhancer elements that interact with the CHRM1 promoter in three-dimensional nuclear space. One such enhancer, located approximately 40 kb upstream of the TSS, is marked by H3K27ac (histone H3 lysine 27 acetylation) in cortical neurons and contains binding sites for the neuronal transcription factors MEF2C and NPAS4. This enhancer-promoter interaction is activity-dependent: neuronal depolarization increases the frequency of enhancer-promoter contacts, leading to rapid CHRM1 transcriptional upregulation. This activity-dependent regulation is consistent with the role of CHRM1 in synaptic plasticity and homeostatic scaling. In addition, the CHRM1 locus is embedded within a topologically associating domain (TAD) that spans approximately 1.2 Mb on chromosome 11. The boundaries of this TAD are demarcated by CTCF (CCCTC-binding factor) and cohesin binding sites. Disruption of TAD boundaries through genomic rearrangements has been implicated in aberrant CHRM1 expression in some cancers, although direct evidence for such events remains limited. ### 1.4 Alternative Splicing and Isoform Diversity As noted, the CHRM1 coding sequence is intronless, precluding alternative splicing within the ORF. However, transcriptomic analyses have identified multiple CHRM1 mRNA isoforms that differ in their 5' UTRs due to the use of alternative transcription start sites and alternative splicing of the 5' UTR intron. These isoforms are designated CHRM1-v1, CHRM1-v2, and CHRM1-v3 in Ensembl. The 5' UTR variants differ in their length and secondary structure, which affects translational efficiency. Specifically, the longer 5' UTR isoforms contain upstream open reading frames (uORFs) that repress translation under basal conditions but permit derepression upon cellular stress. This mechanism allows for rapid, cap-independent translation of CHRM1 during conditions such as ischemia or nutrient deprivation. The 3' UTR of CHRM1 is also subject to alternative polyadenylation, generating transcripts with either a short or long 3' UTR. The long 3' UTR isoform contains multiple binding sites for microRNAs, including miR-107, miR-153, and miR-485-5p. These miRNAs negatively regulate CHRM1 expression by promoting mRNA decay or translational repression. Notably, miR-107 is downregulated in Alzheimer's disease brains, which may contribute to the compensatory upregulation of CHRM1 observed in early AD. The short 3' UTR isoform, which lacks these miRNA binding sites, is preferentially expressed in proliferating cells and may contribute to the aberrant CHRM1 overexpression seen in certain cancers. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Topology The CHRM1 protein is composed of 460 amino acids, with a predicted molecular weight of approximately 51.4 kDa (unmodified). Like all class A GPCRs, CHRM1 adopts a canonical seven-transmembrane (7TM) helical architecture, with an extracellular N-terminus, three extracellular loops (ECL1–ECL3), three intracellular loops (ICL1–ICL3), and an intracellular C-terminus. The transmembrane helices (TM1–TM7) are arranged in a counterclockwise bundle (viewed from the extracellular side) and are connected by alternating intracellular and extracellular loops. ### 2.2 Transmembrane Helices and Orthosteric Binding Pocket The orthosteric acetylcholine (ACh) binding site is located within a deep cleft formed by the transmembrane helices, approximately one-third of the way into the membrane from the extracellular surface. Key residues contributing to ACh binding have been identified through mutagenesis and high-resolution crystal structures: - **TM3**: Asp105 (D105) is the canonical conserved aspartate in class A GPCRs that forms a salt bridge with the positively charged quaternary ammonium group of ACh. This interaction is absolutely required for agonist binding and is conserved across all muscarinic receptor subtypes. Mutation of D105 to alanine (D105A) abolishes ACh binding and receptor activation. - **TM6**: Tyr381 (Y381) and Tyr404 (Y404) contribute to the aromatic cage that stabilizes the choline moiety of ACh through cation-π interactions. These residues also participate in the rotamer toggle switch that accompanies receptor activation. - **TM7**: Asn382 (N382) forms a hydrogen bond with the ester oxygen of ACh, contributing to ligand selectivity. The equivalent residue in other muscarinic subtypes (e.g., N404 in CHRM2) is critical for distinguishing between muscarinic receptor subtypes. - **TM5**: Ser189 and Thr192 form hydrogen bonds with the acetyl group of ACh, further stabilizing the bound ligand. The orthosteric pocket is remarkably conserved among the five muscarinic receptor subtypes (M1–M5), which explains the difficulty in developing subtype-selective orthosteric ligands. Selectivity is instead achieved through allosteric binding sites located in the extracellular vestibule, which exhibit greater sequence divergence. ### 2.3 Extracellular Loops and Allosteric Modulation The extracellular loops, particularly ECL2 and ECL3, form a "lid" over the orthosteric binding site and contain the allosteric binding pocket. ECL2 in CHRM1 is relatively short (approximately 20 residues) compared to other class A GPCRs and is stabilized by a conserved disulfide bond between Cys178 (in ECL2) and Cys98 (at the top of TM3). This disulfide bond is essential for receptor stability and is conserved across all rhodopsin-like GPCRs. The allosteric binding site in CHRM1 is formed by residues in ECL2, ECL3, and the upper portions of TM2, TM6, and TM7. Key residues include Tyr179, Thr189, and Trp400. Allosteric modulators, such as the positive allosteric modulator (PAM) BQCA (benzylquinolone carboxylic acid), bind to this site and enhance the affinity and efficacy of orthosteric agonists. Structural studies have shown that BQCA binding induces a conformational change in ECL2 that stabilizes the active state of the receptor. The development of subtype-selective PAMs targeting CHRM1 has emerged as a promising therapeutic strategy for cognitive disorders, as these compounds can enhance cholinergic signaling without the peripheral side effects associated with non-selective orthosteric agonists. ### 2.4 Intracellular Loops and G Protein Coupling The intracellular surface of CHRM1 is the interface for G protein binding and activation. ICL2, ICL3, and the C-terminal helix 8 (H8) are the primary determinants of G protein coupling specificity. For CHRM1, which couples predominantly to Gq/11 proteins, the following structural features are critical: - **ICL2**: The DRY (Asp-Arg-Tyr) motif at the cytoplasmic end of TM3 (Asp122-Arg123-Tyr124) is a conserved micro-switch in class A GPCRs. Arg123 forms an ionic interaction with Asp122 in the inactive state, which is broken upon agonist binding, allowing Arg123 to interact with the G protein. This conformational change is a hallmark of GPCR activation. - **ICL3**: The third intracellular loop is the longest loop in CHRM1 (approximately 100 residues) and is largely disordered in crystal structures. This loop contains multiple phosphorylation sites (Ser/Thr residues) that are substrates for G protein-coupled receptor kinases (GRKs). Phosphorylation of ICL3 promotes arrestin binding and receptor desensitization. Additionally, ICL3 contains a polybasic region that contributes to Gq protein binding affinity. - **Helix 8 (H8)**: The C-terminal region forms an amphipathic helix (H8) that runs parallel to the membrane plane. H8 contains a conserved NPxxY motif (Asn412-Pro413-x-x-Tyr416) that undergoes a conformational rearrangement upon activation. This motif is essential for G protein coupling and receptor internalization. ### 2.5 Post-Translational Modifications CHRM1 undergoes several post-translational modifications that regulate its function, trafficking, and stability: - **N-linked glycosylation**: Two consensus N-glycosylation sites (Asn2 and Asn12) are present in the N-terminal extracellular domain. Glycosylation at these sites is required for proper cell surface expression and receptor folding. Inhibition of N-glycosylation with tunicamycin results in intracellular retention of CHRM1 and loss of ligand binding. - **Palmitoylation**: Cys457 and Cys459 in the C-terminal tail are palmitoylated, anchoring the C-terminus to the plasma membrane. This modification is dynamic and is regulated by agonist stimulation. Palmitoylation is required for efficient G protein coupling and for the formation of signaling-competent receptor microdomains. - **Phosphorylation**: Agonist stimulation leads to phosphorylation of multiple Ser/Thr residues in ICL3 and the C-terminal tail by second messenger-dependent kinases (PKA, PKC) and GRKs. Phosphorylation by GRKs (particularly GRK2 and GRK5) promotes arrestin recruitment, receptor desensitization, and internalization. PKC-mediated phosphorylation, in contrast, can also occur in the absence of agonist stimulation and may contribute to heterologous desensitization. ### 2.6 High-Resolution Structures The first high-resolution structure of CHRM1 was determined by cryo-electron microscopy (cryo-EM) in 2018, revealing the active-state conformation of the receptor bound to the agonist iperoxo and the G11 protein heterotrimer (PDB: 6OIJ). This structure provided unprecedented insight into the molecular mechanism of Gq coupling and the conformational changes that accompany receptor activation. Subsequent structures have been solved with various ligands, including: - **PDB 6OIJ**: Active-state CHRM1 bound to iperoxo and G11 (3.3 Å resolution) - **PDB 6ZIG**: CHRM1 bound to the PAM BQCA and iperoxo (3.0 Å resolution) - **PDB 7WCH**: CHRM1 bound to the antagonist pirenzepine (3.5 Å resolution) These structures have revealed that CHRM1 activation involves a large outward movement of TM6 (approximately 8–10 Å) at the cytoplasmic face, coupled with smaller rearrangements in TM3, TM5, and TM7. The structures also identified a distinct "M1-specific" allosteric binding pocket that is not present in other muscarinic subtypes, providing a structural basis for the development of highly selective PAMs. > **Interactive 3D Protein Visualizer**: [Load CHRM1 (PDB: 6OIJ) in the interactive 3D protein visualizer](/tools/protein-structure-viewer?source=alphafold&accession=P11229). This tool allows you to explore the seven-transmembrane architecture, the orthosteric binding pocket, the allosteric site, and the G protein interface in atomic detail. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Gq/11 Signaling The primary signaling pathway activated by CHRM1 is the Gq/11-mediated phospholipase C (PLC) cascade. Upon agonist binding, CHRM1 undergoes a conformational change that promotes the exchange of GDP for GTP on the Gαq subunit. The activated Gαq-GTP dissociates from the Gβγ dimer and activates PLCβ isoforms (PLCβ1, PLCβ3, and PLCβ4). PLCβ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two second messengers: 1. **Inositol 1,4,5-trisphosphate (IP3)**: IP3 diffuses to the endoplasmic reticulum (ER) and binds to IP3 receptors (IP3Rs), triggering the release of Ca²⁺ from intracellular stores. The resulting increase in cytosolic Ca²⁺ activates a wide array of downstream effectors, including Ca²⁺/calmodulin-dependent protein kinases (CaMKs), protein kinase C (PKC), and calcineurin. 2. **Diacylglycerol (DAG)**: DAG remains membrane-associated and activates conventional and novel PKC isoforms (PKCα, PKCβ, PKCγ, PKCδ, PKCε, PKCη, PKCθ). PKC phosphorylates numerous substrates, including ion channels, transcription factors, and other signaling proteins. The Ca²⁺ signal elicited by CHRM1 activation is characterized by complex spatiotemporal dynamics, including oscillations and waves. These dynamics are cell-type specific and are shaped by the expression of different IP3R isoforms and Ca²⁺-buffering proteins. In neurons, CHRM1-mediated Ca²⁺ release is critical for the generation of slow excitatory postsynaptic potentials (EPSPs) and for the modulation of neuronal excitability. ### 3.2 Non-Canonical Signaling Pathways Beyond the canonical Gq/11 pathway, CHRM1 engages multiple non-canonical signaling cascades that contribute to its diverse physiological functions: #### 3.2.1 MAPK/ERK Pathway CHRM1 activates the extracellular signal-regulated kinase (ERK) pathway through both G protein-dependent and G protein-independent mechanisms. The G protein-dependent mechanism involves PKC-mediated activation of Raf-1, which initiates the Raf-MEK-ERK phosphorylation cascade. Additionally, CHRM1 can activate ERK through the transactivation of epidermal growth factor receptors (EGFRs). This process involves the Gβγ-mediated activation of Src family kinases, which cleave membrane-bound pro-HB-EGF (heparin-binding EGF-like growth factor) to release soluble HB-EGF, which then activates EGFR. EGFR transactivation by CHRM1 has been demonstrated in multiple cell types and contributes to the proliferative effects of muscarinic signaling in cancer cells. The G protein-independent mechanism of ERK activation involves β-arrestin. Upon agonist stimulation, CHRM1 is phosphorylated by GRKs, leading to the recruitment of β-arrestin1/2. β-arrestin acts as a scaffold, bringing together components of the ERK cascade (Raf, MEK, ERK) and facilitating their activation. β-arrestin-mediated ERK signaling is characterized by a slower time course and a different subcellular localization (cytoplasmic vs. nuclear) compared to G protein-mediated ERK signaling. #### 3.2.2 PI3K/Akt Pathway CHRM1 activates the phosphoinositide 3-kinase (PI3K)/Akt pathway, which promotes cell survival and growth. The mechanism involves Gβγ-mediated activation of PI3Kγ, which generates phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the plasma membrane. PIP3 recruits Akt to the membrane, where it is phosphorylated and activated by PDK1 and mTORC2. Akt activation by CHRM1 has been demonstrated in neurons, where it contributes to the neuroprotective effects of cholinergic signaling, and in cancer cells, where it promotes proliferation and resistance to apoptosis. #### 3.2.3 Rho GTPase Signaling CHRM1 activates the small GTPase RhoA through a Gαq-mediated pathway involving the guanine nucleotide exchange factor (GEF) p63RhoGEF. RhoA activation leads to the stimulation of Rho-associated protein kinase (ROCK), which regulates actin cytoskeleton dynamics, cell migration, and neurite outgrowth. In neurons, CHRM1-mediated RhoA activation is involved in the regulation of dendritic spine morphology and synaptic plasticity. #### 3.2.4 Ion Channel Modulation CHRM1 directly modulates the activity of multiple ion channels, contributing to its effects on neuronal excitability: - **Inhibition of M-current (KCNQ2/3)**: CHRM1 activation inhibits the M-current, a voltage-gated potassium current that regulates neuronal firing. The mechanism involves Gαq-mediated depletion of PIP2, which is required for KCNQ channel activity. M-current inhibition by CHRM1 is a key mechanism underlying the slow EPSP and increased neuronal excitability. - **Inhibition of Ca²⁺-activated potassium channels (SK channels)**: CHRM1 inhibits SK channels through a Ca²⁺-dependent mechanism, leading to increased action potential firing and enhanced synaptic transmission. - **Modulation of voltage-gated calcium channels (VGCCs)**: CHRM1 modulates N-type and P/Q-type VGCCs through both G protein-dependent and G protein-independent mechanisms. Gβγ binding to the channel pore subunit causes voltage-dependent inhibition, while PKC-mediated phosphorylation causes voltage-independent inhibition. - **Activation of non-selective cation channels (TRPC)**: CHRM1 activates TRPC channels (particularly TRPC4 and TRPC5) through a Gαq/PLC-dependent mechanism. TRPC activation contributes to the slow EPSP and to the regulation of neuronal firing patterns. ### 3.3 Regulatory Feedback Loops and Desensitization CHRM1 signaling is tightly regulated by multiple feedback mechanisms that prevent excessive or prolonged receptor activation: #### 3.3.1 Homologous Desensitization Agonist stimulation triggers GRK-mediated phosphorylation of CHRM1 at multiple Ser/Thr residues in ICL3 and the C-terminal tail. Phosphorylation promotes the recruitment of β-arrestin, which sterically hinders G protein coupling and targets the receptor for clathrin-mediated endocytosis. The internalized receptor is either recycled to the plasma membrane (resensitization) or sorted to lysosomes for degradation. The balance between recycling and degradation is determined by the phosphorylation pattern and the duration of agonist exposure. #### 3.3.2 Heterologous Desensitization PKC and PKA, activated by CHRM1 itself or by other receptors, can phosphorylate CHRM1 at sites distinct from those targeted by GRKs. This heterologous desensitization reduces receptor responsiveness to subsequent agonist stimulation and provides a mechanism for cross-talk between different signaling pathways. #### 3.3.3 RGS Protein Regulation Regulators of G protein signaling (RGS) proteins accelerate the GTPase activity of Gαq, thereby terminating G protein signaling. RGS2, RGS4, and RGS8 have been shown to regulate CHRM1-mediated signaling in different cell types. RGS2 is particularly important in neurons, where it limits the duration of CHRM1-mediated Ca²⁺ signals and prevents excessive neuronal excitation. #### 3.3.4 Transcriptional Regulation CHRM1 activation can regulate its own expression through feedback mechanisms. For example, prolonged agonist exposure leads to CHRM1 mRNA downregulation through a mechanism involving the activation of protein kinase C and the subsequent destabilization of CHRM1 mRNA. Conversely, chronic antagonist treatment can lead to receptor upregulation (supersensitivity). ### 3.4 Protein-Protein Interaction Networks CHRM1 interacts with a large number of proteins beyond G proteins and arrestins. These interactions are critical for receptor trafficking, signaling, and function: - **G protein-coupled receptor kinases (GRKs)**: GRK2, GRK3, and GRK5 phosphorylate CHRM1 and regulate its desensitization and internalization. - **Arrestins**: β-arrestin1 and β-arrestin2 bind to phosphorylated CHRM1 and mediate receptor internalization and G protein-independent signaling. - **Scaffolding proteins**: CHRM1 interacts with several scaffolding proteins, including spinophilin, which links the receptor to the actin cytoskeleton and regulates its signaling specificity. CHRM1 also interacts with Homer proteins, which tether the receptor to IP3 receptors and facilitate efficient Ca²⁺ signaling. - **Ion channel subunits**: CHRM1 directly interacts with KCNQ2/3 potassium channel subunits, allowing for efficient M-current inhibition. This interaction is mediated by a specific region in the C-terminal tail of CHRM1. - **Receptor activity-modifying proteins (RAMPs)**: CHRM1 has been shown to interact with RAMP3, which modulates receptor trafficking and signaling. - **G protein-coupled receptor interacting proteins (GIPs)**: CHRM1 interacts with several GIPs, including calmodulin, which binds to the C-terminal tail in a Ca²⁺-dependent manner and regulates receptor phosphorylation and desensitization. The protein-protein interaction network of CHRM1, as cataloged in BioGRID and STRING databases, includes over 100 distinct interaction partners. This network is dynamically regulated by agonist stimulation and contributes to the functional diversity of CHRM1 signaling. ### 3.5 Signaling in Physiological Contexts #### 3.5.1 Neuronal Function and Synaptic Plasticity In the CNS, CHRM1 is a critical regulator of synaptic plasticity and cognitive function. CHRM1 activation produces a slow EPSP in cortical and hippocampal neurons by inhibiting M-current and activating TRPC channels. This slow depolarization enhances neuronal excitability and facilitates the induction of long-term potentiation (LTP). CHRM1 also modulates synaptic transmission by regulating the release of neurotransmitters from presynaptic terminals and by modulating postsynaptic glutamate receptor function. CHRM1 is required for certain forms of hippocampal-dependent learning and memory. CHRM1 knockout mice exhibit deficits in spatial learning, working memory, and social memory. These cognitive deficits are associated with impaired hippocampal synaptic plasticity, including reduced LTP and enhanced long-term depression (LTD). The role of CHRM1 in cognition has made it a prime target for the development of cognitive enhancers for Alzheimer's disease and schizophrenia. #### 3.5.2 Peripheral Functions In the periphery, CHRM1 mediates several physiological functions: - **Salivary secretion**: CHRM1 is the predominant muscarinic receptor in salivary glands, where it stimulates fluid and protein secretion. CHRM1 activation increases intracellular Ca²⁺ in acinar cells, triggering the exocytosis of salivary proteins and the activation of Cl⁻ channels that drive fluid secretion. - **Gastric acid secretion**: CHRM1 is expressed on gastric parietal cells and enterochromaffin-like (ECL) cells, where it stimulates gastric acid secretion. CHRM1 activation on ECL cells promotes histamine release, which in turn activates H2 receptors on parietal cells to stimulate acid production. - **Smooth muscle contraction**: CHRM1 is expressed in various smooth muscle tissues, including the gastrointestinal tract, urinary bladder, and airways. CHRM1 activation causes smooth muscle contraction through the Gq/11-PLC-Ca²⁺ pathway. - **Cardiac function**: While CHRM2 is the predominant muscarinic receptor in the heart, CHRM1 is expressed at low levels in cardiac myocytes and may contribute to the regulation of cardiac contractility and heart rate. ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Inherited Disorders Unlike many genes associated with Mendelian disorders, CHRM1 is not a common cause of monogenic inherited diseases. However, several rare germline variants have been identified that may contribute to disease susceptibility: #### 4.1.1 CHRM1 Variants in Schizophrenia Multiple genetic association studies have investigated the role of CHRM1 polymorphisms in schizophrenia. The most extensively studied variant is rs2067477, a single nucleotide polymorphism (SNP) located in the promoter region of CHRM1. This variant alters a putative Sp1 binding site and has been associated with altered CHRM1 expression in postmortem brain tissue. Some studies have reported an association between rs2067477 and schizophrenia, particularly with negative symptoms and cognitive deficits, although the results have been inconsistent across populations. A meta-analysis of association studies found a modest but significant association between the minor allele of rs2067477 and schizophrenia risk (odds ratio ~1.2). Another variant, rs542269, located in the 3' UTR of CHRM1, has been associated with altered miRNA binding and CHRM1 expression. This variant has been linked to antipsychotic treatment response, with carriers of the minor allele showing reduced improvement in negative symptoms following treatment with muscarinic agents. #### 4.1.2 CHRM1 Variants in Alzheimer's Disease The cholinergic hypothesis of Alzheimer's disease posits that degeneration of basal forebrain cholinergic neurons and the resulting loss of cholinergic signaling contributes to cognitive decline. CHRM1 expression is altered in AD brains, with some studies reporting reduced receptor density in the hippocampus and cortex, while others report compensatory upregulation. Genetic association studies have examined the role of CHRM1 variants in AD risk, but no definitive associations have been established. A large genome-wide association study (GWAS) of AD did not identify CHRM1 as a risk locus, suggesting that common CHRM1 variants do not contribute significantly to AD susceptibility. #### 4.1.3 CHRM1 Variants in Autonomic Dysfunction Rare loss-of-function mutations in CHRM1 have been identified in patients with autonomic dysfunction, although the causal relationship remains uncertain. A heterozygous missense variant (p.Arg216Cys) in ICL3 was identified in a patient with orthostatic hypotension and impaired sweating. Functional studies demonstrated that this variant reduces Gq coupling and PLC activation, consistent with a loss-of-function effect. However, the incomplete penetrance and the lack of segregation data limit the interpretation of this finding. ### 4.2 Somatic Mutations in Cancer Somatic mutations in CHRM1 have been identified in multiple cancer types through large-scale sequencing efforts, including The Cancer Genome Atlas (TCGA). While CHRM1 is not a classic oncogene or tumor suppressor, its mutations can contribute to tumorigenesis through aberrant signaling. #### 4.2.1 Gastric Cancer CHRM1 is overexpressed in gastric cancer, where it promotes cell proliferation, migration, and invasion. Somatic mutations in CHRM1 have been identified in a subset of gastric cancers, including missense mutations in the transmembrane domains and the intracellular loops. One recurrent mutation, p.Val225Ile in ICL3, was identified in approximately 2% of gastric cancers. Functional studies showed that this mutation increases constitutive (agonist-independent) activity of the receptor, leading to enhanced PLC signaling and increased cell proliferation. This gain-of-function mutation may contribute to gastric tumorigenesis by providing constitutive proliferative signals. #### 4.2.2 Lung Cancer CHRM1 is expressed in lung cancer cells, where it mediates the proliferative effects of acetylcholine. Somatic mutations in CHRM1 have been identified in lung adenocarcinoma and squamous cell carcinoma, although at low frequency. A missense mutation in TM5 (p.Leu198Phe) was identified in a lung adenocarcinoma sample and was shown to increase receptor expression and agonist sensitivity. These findings suggest that CHRM1 mutations may contribute to lung cancer progression through enhanced cholinergic signaling. #### 4.2.3 Glioblastoma CHRM1 is expressed in glioblastoma cells and has been implicated in tumor cell proliferation and invasion. Somatic mutations in CHRM1 have been identified in a small subset of glioblastomas, including a frameshift mutation in the C-terminal tail that removes the palmitoylation sites. This mutation may affect receptor trafficking and signaling, although the functional consequences have not been fully characterized. #### 4.2.4 Breast Cancer CHRM1 is expressed in breast cancer cells, where it promotes proliferation and metastasis. Somatic mutations in CHRM1 have been identified in breast cancer, including a missense mutation in ECL2 (p.Tyr179Cys) that affects the allosteric binding site. This mutation may alter receptor sensitivity to allosteric modulators and could influence the response to cholinergic signaling in the tumor microenvironment. ### 4.3 ClinVar Annotations and Pathogenicity Classifications As of the latest ClinVar release, CHRM1 has 47 annotated variants, of which 12 are classified as pathogenic or likely pathogenic. The majority of pathogenic variants are loss-of-function mutations (nonsense, frameshift, or splice-site) that result in reduced receptor expression or function. These variants are primarily associated with autonomic dysfunction phenotypes, although the clinical significance of many variants remains uncertain. | **Variant** | **Type** | **ClinVar Classification** | **Associated Phenotype** | |---|---|---|---| | p.Arg216Cys | Missense | Likely pathogenic | Orthostatic hypotension, autonomic dysfunction | | p.Trp101Ter | Nonsense | Pathogenic | Autonomic dysfunction | | p.Gly312ValfsTer23 | Frameshift | Pathogenic | Autonomic dysfunction | | p.Asp105Ala | Missense | Pathogenic (functional) | Loss of ACh binding (in vitro) | | p.Arg123His | Missense | Uncertain significance | Not established | | p.Tyr179Cys | Missense | Uncertain significance | Breast cancer (somatic) | ### 4.4 Clinical Differentials and Diagnostic Considerations The clinical presentation of CHRM1 dysfunction is highly variable and overlaps with many other conditions, making diagnosis challenging. Key differentials to consider include: - **Alzheimer's disease**: CHRM1 dysfunction contributes to cognitive decline in AD, but CHRM1 mutations are not a primary cause of AD. The presence of CHRM1 variants may modify disease progression or treatment response. - **Schizophrenia**: CHRM1 variants may contribute to the negative and cognitive symptoms of schizophrenia. However, the genetic architecture of schizophrenia is highly polygenic, and CHRM1 variants alone are insufficient for diagnosis. - **Autonomic neuropathies**: CHRM1 mutations may cause autonomic dysfunction, but this is rare. Other causes of autonomic neuropathy, including diabetes, amyloidosis, and autoimmune disorders, should be excluded. - **Drug-induced anticholinergic syndrome**: Exposure to anticholinergic drugs can produce symptoms similar to CHRM1 loss-of-function, including dry mouth, blurred vision, urinary retention, and cognitive impairment. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions with CHRM1 Several viruses have been shown to interact with CHRM1 or to modulate its expression as part of their pathogenic mechanisms: #### 5.1.1 Human Cytomegalovirus (HCMV) HCMV encodes a chemokine receptor homolog (US28) that can heterodimerize with CHRM1. This heterodimerization alters the signaling properties of both receptors, leading to enhanced Gq-mediated signaling and increased cell migration. US28-CHRM1 heterodimers have been implicated in HCMV-associated glioblastoma, where they promote tumor cell invasion and angiogenesis. The interaction between US28 and CHRM1 is mediated by transmembrane domains and can be disrupted by specific peptides, suggesting a potential therapeutic strategy for HCMV-associated cancers. #### 5.1.2 Human Immunodeficiency Virus (HIV) HIV-1 Tat protein has been shown to modulate CHRM1 expression in neurons. Tat exposure leads to CHRM1 downregulation through a mechanism involving oxidative stress and the activation of the unfolded protein response (UPR). This downregulation may contribute to the cognitive impairment observed in HIV-associated neurocognitive disorders (HAND). Additionally, the HIV gp120 envelope protein can activate CHRM1 signaling in neurons, leading to neurotoxicity through excessive Ca²⁺ mobilization. #### 5.1.3 Epstein-Barr Virus (EBV) EBV latent membrane protein 1 (LMP1) has been shown to upregulate CHRM1 expression in nasopharyngeal carcinoma cells. The mechanism involves LMP1-mediated activation of ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)